An advanced non-small cell lung cancer patient with EGFR and KRAS mutations, and PD-L1 positive, benefited from immunotherapy: a case report

BACKGROUND: Patients with epidermal growth factor receptor (EGFR)-sensitive mutations have great opportunity to benefit from EGFR-tyrosine kinase inhibitors (TKI) in non-small cell lung cancer (NSCLC). Although the presence of Kirsten rat sarcoma virus (KRAS) mutations is predictive of lack of benef...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Ronghua, Wang, Dong, Li, Xia, Mao, Kaiping, Wang, Jinglong, Li, Peng, Shi, Xiaoliang, Zhang, Shanshan, Wang, Yongjie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9011273/
https://www.ncbi.nlm.nih.gov/pubmed/35433927
http://dx.doi.org/10.21037/atm-22-403

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9011273/
https://www.ncbi.nlm.nih.gov/pubmed/35433927
http://dx.doi.org/10.21037/atm-22-403

Ejemplares similares